Telix Pharmaceuticals Limited (NASDAQ:TLX) , a therapeutic and diagnostic radiopharmaceuticals company, on Tuesday reported its full-year revenue. • Telix Pharmaceuticals stock is testing lower boundaries. Why is TLX stock at lows?Telix Hits FY 2025 Revenue TargetAustralia-based Telix Pharmaceuticals reported fiscal 2025 revenue of approximately $804 million, aligning with its upgraded guidance of$800-$820 million.The company also noted a significant 46% year-over-year increase in the fourth quarter revenu ...